ONCOLOGY

Analysis of 2 phase 3 trials shows better PFS than high-dose irinotecan alone.

Meta-analysis of 52 observational studies.

Study casts doubt on the benefit of prophylactic gastrectomy.

Further studies of the treatment for HER2-low breast cancer and other HER2-expressing cancers are planned.

Nevertheless, the NEO-CLASSIC study did not meet its primary endpoint.

First phase 2 randomized trial of add-on lapatinib with perioperative chemotherapy.

No solitary pulmonary metastases detected in absence of other metastatic sites.

Especially use for over 36 months or after H pylori eradication.

Gastric cancer is the fifth most frequently diagnosed cancer worldwide, with a poor outcome after surgery.

The Chinese CLASS-01 RCT finds no differences in 3-year DFS, OS, and recurrence.

Combination tops surgery alone in patients with peritoneal metastases.

A change in the standard of care.

Data from the FLOT4 trial.

Data from the European Prospective Investigation into Cancer and Nutrition cohort.